Regional and supply-chain research

Medical Device Keyword Candidate Study

Medical Device Keyword Candidate Study. A dated 1,301-record cohort study compares composition, parent sets and evidence coverage. Comparative structure study; archive date 2026-10-16.

Revision and archive snapshot: 2026-10-16

Swipe tables sideways to see all columns.

Research findings

Comparative structure study

The largest recorded reporting jurisdiction, Jiangsu, contains 219 records (16.8% of this 1,301-record cohort). The remaining cohort contains 1,082 records. The comparison concerns archive composition.

The recorded industry label Biomedicine accounts for 69.3% here (902/1,301), compared with 8.9% in the parent set (1,721/19,297), an absolute gap of 60.4 percentage points.

461/1,301 companies link to pages with existing source-supported excerpts (35.4% of the cohort). The other 840 records remain usable for archive composition, but do not support new operating case studies.

3 keyword candidates match only a company name, with no matching term in recorded products or sub-industry fields. Product evidence is needed before treating these as operating businesses in this segment.

Company cohortDirectly linked pagesShare of public archiveArchive date
1,3011,3016.7%2026-10-16

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

Comparable sets and compositional differences

The parent set, All public archive records, contains 19,297 records. This cohort contributes 1,301 (6.7%); 17,996 records remain after excluding it.

CategoryCohort count/baseReference: All public archive recordsGap (pp)Representation ratioRest count/base
industry · Biomedicine902/1,301 · 69.3%1,721/19,297 · 8.9%+60.47.77819/17,996
chain role · Biomedicine and medical devices / Complete systems and use-case applications613/1,301 · 47.1%1,373/19,297 · 7.1%+40.06.62760/17,996
industry · Advanced equipment129/1,301 · 9.9%4,918/19,297 · 25.5%-15.60.394,789/17,996
industry · Next-generation information technology150/1,301 · 11.5%5,226/19,297 · 27.1%-15.60.435,076/17,996
industry · Advanced materials29/1,301 · 2.2%3,381/19,297 · 17.5%-15.30.133,352/17,996
chain role · Advanced materials / Basic and process materials23/1,301 · 1.8%2,854/19,297 · 14.8%-13.00.122,831/17,996
chain role · Electronic information and digital technology / Core components and digital hardware46/1,301 · 3.5%3,137/19,297 · 16.3%-12.70.223,091/17,996
sub-industry · Electronic assemblies and systems integration8/1,301 · 0.6%1,188/19,297 · 6.2%-5.50.101,180/17,996
sub-industry · Industrial software and information services7/1,301 · 0.5%906/19,297 · 4.7%-4.20.11899/17,996
sub-industry · Biomedicine91/1,301 · 7.0%699/19,297 · 3.6%+3.41.93608/17,996

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded industry label Biomedicine covers 819/17,996 remaining records (4.6%), an absolute gap of 64.8 percentage points from this cohort.

Concentration and cross-sectional structure

The full reporting jurisdiction distribution has 34 labels; the top 3 contain 470/1,301 records (36.1%).Other known labels contain 831 records.

For 1,301 records with known labels, the effective category count is 12.8, versus 34 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 24 others are included in the calculations above.

Recorded labelRecordsShare of cohort
Jiangsu21916.8%
Shenzhen1299.9%
Beijing1229.4%
Zhejiang1168.9%
Shanghai1058.1%
Guangdong1058.1%
Shandong816.2%
Hubei403.1%
Anhui372.8%
Sichuan352.7%

Record counts do not rank supply capability or economic size.

The largest intersection, Jiangsu × Biomedicine, contains 151 records, or 68.9% of the 219 records carrying the Jiangsu label.

reporting jurisdictionindustryIntersection recordsCohort share
JiangsuBiomedicine15111.6%
BeijingBiomedicine1027.8%
ZhejiangBiomedicine836.4%
ShanghaiBiomedicine796.1%
ShenzhenBiomedicine796.1%
GuangdongBiomedicine574.4%
ShandongBiomedicine534.1%
HunanBiomedicine282.2%

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 146 non-empty cells; the other 138 remain in the analysis.

Evidence coverage and strength of conclusions

Record fieldNon-empty/cohortCompletion
Company name1,301/1,301100.0%
reporting jurisdiction1,301/1,301100.0%
industry1,301/1,301100.0%
Recorded products1,301/1,301100.0%
sub-industry1,301/1,301100.0%
Chain labels1,301/1,301100.0%

Non-empty fields are not necessarily accurate or supported by originals.

Scope of source supportCount
Profiles with source-supported excerpts461
Distinct corresponding companies461
Reviewed Chinese/English paragraph pairs478

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

Transparent rule reminderRecordsCohort share
Contains registration-narrative wording413.2%
Only generic operations vocabulary remains141.1%

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

Matched fieldCandidatesCohort share
Company name13610.5%
Recorded products75157.7%
Sub-industry1,06481.8%

An ID may match several fields, so counts may exceed the cohort total. Matches establish search relevance only.

Among the translated non-broad query terms, “medical devices” has the most matches: 1,134/1,301. Name, product and sub-industry fields match 90, 615 and 966 records respectively; the largest field is sub-industry label. Fields can overlap, and a term remains a search link rather than verified business activity.

Selected query termCandidates/shareName matchesProduct fieldSub-industry
medical devices1,134 · 87.2%90615966

Selected broad terms and specific segment terms, not the full query. Terms and fields can overlap and must not be summed. Counts show lexical sensitivity; no records are removed without primary evidence.

3 candidates match only a name, or lose all product-field matches after the full company name is removed while sub-industry also has no hit. This transparent string test locates copied company descriptions; it does not establish that a company does not operate the business.

1 records have a documented classification-consistency question. Original counts remain 1,301; excluding these records leaves 1,300 in the sensitivity calculation. The study does not reclassify firms or treat label conflicts as operating changes.

Intersection with 2026 local lists

283 of this cohort’s 1,301 records link through existing company-ID mappings to 2026 lists from all jurisdictions (21.8%). This intersection measures list linkage, not successful recognition or company growth.

Observation setList recordsNew-applicant recordsReview recordsMapped company IDs
National list records linked to this cohort’s IDs2835278283

List rows and company IDs are separate counts, not new firms or final recognition.

Stored 2026 local-recommendation records, sources and stage definitions

Recorded roles and delivery checks

Device research must verify the specific product scope

The Advanced medical devices label covers 878 records (67.5% of this cohort). This archive clue raises a verification question about Specific devices with corresponding product and quality-technical documents; it does not establish that these companies already deliver it.

Delivery framework, stages and original sources

Related studies and shared records

Shared records with High End Medical Device Keyword Candidate Study: 949; records in this cohort but outside that set: 352. The intersection/union ratio is 72.3%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Biomedicine and medical devices / Complete systems and use-case applications Supply-chain Study: 613; records in this cohort but outside that set: 688. The intersection/union ratio is 29.7%, a measure of label overlap rather than business collaboration. Read comparison

Company samples and record links

Stable-ID samples, not rankings; metrics use the full cohort.

Directly related profiles and reports

Methodology

Read ID deduplication, comparison, batch and evidence definitions